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DOI 10.1016/j.cmet.2012.02.005We would like to respond to Brosch
et al. regarding our manuscript ‘‘Expres-
sion of the Splicing Factor Gene SFRS10
Is Reduced in Human Obesity and Con-
tributes to Enhanced Lipogenesis’’ (Pihla-
jama¨ki et al., 2011b). Brosch performed
RT-PCR in liver samples from 13 lean
and34 obese individuals, finding nodiffer-
ences inSFRS10or LPIN1 expression.We
wish to address points raised by Brosch,
including experimental strategy and anal-
ysis of human SFRS10 expression.
Experimental Strategy
Our overall goal was to identify genes or
pathways altered in key insulin-responsive
tissues in obese humans with or without
type 2 diabetes (T2D). Liver biopsies were
obtained during elective surgery from indi-
viduals who also had glucose tolerance
testing (to define undiagnosed T2D). With
this approach, we achieved an initial
cohort of 13 metabolically characterized
individuals. Based on our prior observa-
tions (Patti et al., 2003), we recognized
we would have limited power to detect
single differentially expressed genes with
this sample size. For this reason, and
because no single gene is likely respon-
sible for complex disorders such as
obesity and T2D, we planned pathway-
based analysis, as described in human
T2D expression studies (Patti et al., 2003;
Mootha et al., 2003). Our manuscript
details pathway analysis, pattern valida-tion in mice, hypothesis development,
and selection of single genes for testing
the hypothesis that splicing factors could
contribute to metabolic phenotypes.
Single Gene Analysis
A human liver array study with 13 samples
has limited power to identify single differ-
entially expressed genes. Few, if any,
would ever be expected to reach the
Bonferroni-corrected p value suggested
by Brosch (p < 3.53 106); this approach
is not typically utilized for microarray
analysis, due to the high number of
comparisons (e.g., 14,500 probes). For
single-gene analysis, we calculated q
values (Bioconductor multitest function,
Benjamini-Hochberg correction for multi-
ple comparisons). As seen in Figure S1A,
one SFRS10 probe set demonstrated
37% reduction in expression in obese
humans (200893_at, q = 2.5 3 103),
while another was 25% lower in obesity
(200892_s_at, q = 0.09). A third probe
set (210180_s_at) was not analyzed, as
its signal was near background (lean,
42 ± 18 versus OB, 50 ± 17). We empha-
size that SFRS10 was not selected due
to differential expression across the entire
microarray, but due to its role as member
of RNA processing gene set (n = 199)
identified in pathway analysis.
Pathway Analysis
Pathway-based approaches (GenMAPP,
GSEA) identified significant downregu-
lation of genes of RNA processing andCell Metabolismsplicing in obese subjects (e.g.,
GenMAPP, Z7.5 RNA splicing, adjusted p
< 0.001; GSEA, RNA processing set
enriched, FDR 0.039) and correlation of
thisontology to lipidaccumulation.Further
support came from parallel independent
observations of downregulation of RNA
processing genes inmuscle fromaFinnish
population (GenMAPP Z11.5 RNA
splicing, adjusted p < 0.001). Our collabo-
ration was initiated when we viewed each
other’s data at an international meeting;
these concordant patterns in two human
populations led to our studies.
Rationale for Further SFRS10
Analysis
These independent human observations
and similar patterns inmurine obesity sug-
gested a potential link between RNA pro-
cessing and obesity-related metabolism
(as shown in Figure 1 of Pihlajama¨ki et al.,
2011b). Although therewere several genes
of interest within the overlapping set of
RNA processing genes, SFRS10 was
a candidate of great interest as: (1) expres-
sion was downregulated in liver and
muscle in obese humans and mice
(Figures 1B and 1C [Pihlajama¨ki et al.,
2011b]), (2) expression in liver significantly
correlated with BMI (r = 0.73, Table S3
[Pihlajama¨ki et al., 2011b]), (3) protein
expression was significantly decreased in
obese mouse liver (Figure 1D [Pihlajama¨ki
et al., 2011b]), (4) expression was altered
by chronic insulin in HepG2 cells (Figure 115, March 7, 2012 ª2012 Elsevier Inc. 267
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targeting SFRS10 increased lipogenesis,
expression of lipogenic genes, and lipid
content versus scrambled siRNA-treated
cells (Figure 2 [Pihlajama¨ki et al., 2011b]).
By contrast, knockdown of a constitutive
splicing factor (SF3A1) did not alter triglyc-
eride content or lipogenic expression
(Figures S2A and S2B [Pihlajama¨ki et al.,
2011b]). Guided by Cell Metabolism peer
reviewers, we tested the role of SFRS10
in vivo. These studies demonstrated that
SFRS10heterozygousmice had upregula-
tion of multiple lipogenic genes (concor-
dant with cellular knockdown) and
increased plasma VLDL (Figure 3 [Pihlaja-
ma¨ki et al., 2011b]), supporting a physio-
logical role forSFRS10. Thus, several inde-
pendent observations in humans, cells,
and mice validated the selection of
SFRS10 as candidate for further studies.
Analysis of SFRS10 Expression
by PCR
Brosch and colleagues analyzed a
cohort of 47 human liver samples using
PCR. While substantial inter-individual
variation, as expected for human popula-
tions, could limit power to detect differen-
tial expression of SFRS10, we believe that
several distinct mechanisms are likely
to be responsible for differences in results:
Patient Population and Biopsy
Approach
Our cohort compared a lean group (mean
BMI 24) with an extremely obese group
(mean BMI 53), of whom four had T2D
diagnosed during study. The number of
subjects with T2D in the Brosch cohort
is not provided. Given that chronic insulin
exposure reduced expression of SFRS10
in cells (Figure 1 [Pihlajama¨ki et al.,
2011b]), it is possible that substantially
increased fasting insulin levels in obese
subjects (mean 148 pM, Table 1 [Pihlaja-
ma¨ki et al., 2011b]) might contribute to
reduced SFRS10 expression, as sug-
gested by the significant correlation
between fasting insulin and liver SFRS10
expression (r = 0.54, Table S4 [Pihlaja-
ma¨ki et al., 2011b]). Fasting insulin also
correlated with expression of six other
RNA processing genes (Table S4 [Pihlaja-
ma¨ki et al., 2011b]). Together, these data
suggest that more marked elevations in
circulating insulin, associated with severe
obesity, insulin resistance, and T2D, may
have contributed to differences between
study populations.268 Cell Metabolism 15, March 7, 2012 ª201Our biopsies were taken in the fasting
state during elective abdominal surgery,
with general anesthesia, whereas Brosch
obtained biopsies both during surgery
and via percutaneous approaches. Were
all performed in the fasting state? Were
lean or postbypass individuals more likely
to have had percutaneous, and obese
subjects surgical, biopsies? If so, expres-
sion data may not be directly comparable
across BMI ranges.
PCR Quantification of SFRS10
Variants
PCR analysis of SFRS10 mRNA expres-
sion iscomplex.SFRS10hasmultiplealter-
natively spliced mRNA variants (17 in
current Ensembl browser), which play an
important role in the known autoregulation
of SFRS10 protein (Stoilov et al., 2004).
When present at high levels, SFRS10binds
its own exon 2, activating its inclusion and
generating the Tra2b4 transcript, which is
not translated due to a stop codon. Con-
versely, if SFRS10 protein is low, exon 2 is
skipped, favoring the functionalTra2b1 iso-
form (Figure S4 [Pihlajama¨ki et al., 2011b]).
Brosch tested expression of SFRS10
using a 50 (forward) primer spanning exons
1–3 and 30 (reverse) primer in exon 4
(Figure S1B). This leads to one PCR
product, for Tra2b1 (Figure 1A in Brosch
et al., 2012), but would not detect
Tra2b4. By contrast, the microarray quan-
tified total Tra2b or all isoforms containing
the common 30 UTR, including both
Tra2b1andTra2b4.Due toautoregulation,
these differences in primer location are
probably crucial. For example, the magni-
tudes of decreases in untranslated Tra2b4
are greater than for Tra2b1 in both
SFRS10 heterozygous mice and SFRS10
knockdown cells (Figure S4B of Pihlaja-
ma¨ki et al., 2011b and Figures S1C and
S1D). Therefore, it is possible that differ-
ences in relative expression of these vari-
ants underlie differences between our
findings. Differences in relative abun-
dance of SFRS10 isoforms may also alter
splicing of downstream targets, including
Lpin1. RNA sequencing may be helpful to
directly address these possibilities.
We have now performed additional
PCR-capillary electrophoresis to detect
proportions of Tra2b1 and Tra2b4 with
primers in exons 1 and 3 spanning alter-
natively spliced exon 2 (Figure S1B). Liver
samples from 73 individuals (age 45.8 ±
7.8, BMI 45.1 ± 6.1, 24 male/49 female,
described in Pihlajama¨ki et al., 2011a)2 Elsevier Inc.were used. Although this data set does
not include lean individuals, the propor-
tion of Tra2b1 (without exon 2) correlated
inversely with BMI (r = 0.249, p = 0.035)
(Figure S1E). RT-PCR using primers
in exons 7 and 8 did not demonstrate
similar association. This provides addi-
tional validation of the association
between SFRS10 variants and obesity
and highlights the complex regulation of
SFRS10 variants that potentially contrib-
utes to differences between our studies.
Additional Comments
Brosch and colleagues note that ‘‘only 2
of the 13 genes showed a similar change
of expression [in mice] as seen in
humans.’’ This is not correct. We tested
expression of 5 genes (identified from
human array analysis) in obese mice and
found significantly reduced expression
of 5 of 5 in liver and 4 of 5 in muscle
(Figure 1C of Pihlajama¨ki et al., 2011b).
We also wish to clarify that additional
samples used for LPIN1b/a ratio determi-
nation were obtained from 6 lean and 14
obese subjects of a cohort with similar
metabolic profile described in a previous
manuscript (Table S1 [Pihlajama¨ki et al.,
2009]).
Together, we appreciate the work of
Brosch to examine SFRS10 expression in
an additional cohort. Differences in patient
population, methods to detect SFRS10
mRNA variants, and complicated autore-
gulation of SFRS10 are all likely contribu-
tors to differences between our findings.
We fully acknowledge that experimental
analysis in cells andmice does not provide
direct evidence for significance in humans
and look forward to future studies further
addressing the role of SFRS10 in humans.
SUPPLEMENTAL INFORMATION
Supplemental Information includes one figure and
can be found with this article online at doi:10.
1016/j.cmet.2012.02.005.
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DOI 10.1016/j.cmet.2012.02.003We read with great interest the paper by
Matsubara and collaborators defining a
new function for progranulin as an adipo-
kine potentiating high-fat diet-mediated
insulin resistance through IL-6 (Matsu-
bara et al., 2012). We would like to draw
the attention of the reader to the potential
relevance of these findings for the neuro-
degenerative diseases fronto-temporal
dementia (FTD) and amyotrophic lateral
sclerosis (ALS).
FTD, the most common cause of
dementia in the elderly after Alzheimer’s
disease, is characterized by the degener-
ation of neurons in the frontal and tem-
poral lobes of the brain leading to a range
of behavioral symptoms. FTD co-occurs
with ALS in multiple families, sometimes
in the same patient, and both diseases
share common genetic causes and similar
pathological lesions, suggesting that
they represent two extremes of a clinical
spectrum. Null mutations in the progranu-
lin gene are the most frequent cause of
familial FTD (Cruts et al., 2006), and pro-
granulin genetic variation is also amodifier
of age of onset and disease duration in
ALS (Sleegers et al., 2008). Matsubara’s
findings may therefore have implications
for our understanding of FTD and ALS.
First, loss of progranulin in progranulin
mutant FTD patients could cause aperipheral energymetabolism phenotype.
Indeed, decreased peripheral levels of
progranulin are observed in progranulin
mutant FTD patients (Schofield et al.,
2010). Matsubara and collaborators
report that progranulin knockout mice
are resistant to high-fat diet (HFD) and
display decreased IL-6 levels, thereby
increasing insulin sensitivity upon HFD.
Whether loss of progranulin leads to
similar consequences in FTD patients
harboring a progranulin mutation is un-
known, and to our knowledge no study
has focused on adipose tissue in FTD
patients. Interestingly, abnormal eating
behavior, including overeating and prefer-
ence for sweet food, is a typical symptom
of the behavioral variant of FTD and is
associated with hypothalamic degenera-
tion (Piguet et al., 2011). Contrasting
with the results of Matsubara, proganulin
mutant FTD patients displayed increased
circulating IL-6 levels (Bossu` et al.,
2011), but confounding dietary and/or
endocrine factors were not studied.
Hence, Matsubara’s findings call for a
complete metabolic phenotyping of FTD
patients. Importantly, such studies were
performed in ALS and led to the conclu-
sion that peripheral energy deficit precip-
itates neurodegeneration in this disease.
This paved the way for several clinicaltrials targeting nutrition in this disease
(Dupuis et al., 2011). In all, the potential
dysregulation of energy homeostasis in
progranulin-mediated FTD as well as its
contribution to the neurodegeneration
warrants further investigation.
Matsubara’s findings also have potential
consequences for the design of
therapeutic strategies in FTD. A very
straightforward therapeutic strategy for
FTD would be to stimulate the expression
of progranulin from the nonmutant allele.
Recent studies identifiedseveral candidate
drugs, including inhibitors of the v-ATPase,
as possible inducers of progranulin secre-
tion (Capell et al., 2011). In the brain, such
increasedprogranulin releasewouldbeex-
pected to yield neuroprotection (Van
Damme et al., 2008); Matsubara’s findings
suggest, however, that a potential side
effect of such a treatment could be the
development of insulin resistance. This
should be taken into account in the design
of potential clinical trials in FTD.
In summary, the results of Matsubara
and colleagues are of direct interest not
only for increasing the understanding of
the pathomechanisms of insulin resis-
tance as explicitly stated by the authors,
but also for the two diseases currently
genetically associated with progranulin,
namely FTD and ALS.15, March 7, 2012 ª2012 Elsevier Inc. 269
